Vivo Capital LLC purchased a new stake in Chiasma Inc (NASDAQ:CHMA) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,377,213 shares of the biotechnology company’s stock, valued at approximately $17,758,000. Chiasma comprises 1.7% of Vivo Capital LLC’s holdings, making the stock its 19th biggest holding. Vivo Capital LLC owned about 7.48% of Chiasma at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CHMA. Millennium Management LLC acquired a new stake in Chiasma in the fourth quarter worth about $41,000. Quantitative Systematic Strategies LLC bought a new position in shares of Chiasma during the 2nd quarter valued at about $100,000. Deutsche Bank AG lifted its holdings in shares of Chiasma by 27.8% during the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 16,996 shares in the last quarter. Wells Fargo & Company MN bought a new stake in Chiasma in the 2nd quarter valued at approximately $237,000. Finally, JPMorgan Chase & Co. lifted its stake in Chiasma by 242.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,139 shares of the biotechnology company’s stock valued at $545,000 after acquiring an additional 51,806 shares in the last quarter. 53.19% of the stock is owned by institutional investors and hedge funds.

Chiasma stock traded down $0.05 during mid-day trading on Friday, reaching $5.19. The stock had a trading volume of 18,718 shares, compared to its average volume of 395,653. Chiasma Inc has a fifty-two week low of $2.11 and a fifty-two week high of $9.25. The stock’s 50-day simple moving average is $5.22 and its 200-day simple moving average is $6.07. The firm has a market capitalization of $221.55 million, a PE ratio of -3.95 and a beta of 1.19.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.04. As a group, equities research analysts expect that Chiasma Inc will post -1.09 earnings per share for the current year.

In other Chiasma news, Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $6.35, for a total transaction of $63,500.00. Following the completion of the sale, the director now owns 10,000 shares of the company’s stock, valued at $63,500. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Scott Minick purchased 9,818 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average cost of $5.19 per share, with a total value of $50,955.42. Following the purchase, the director now owns 62,531 shares of the company’s stock, valued at $324,535.89. The disclosure for this purchase can be found here. 8.30% of the stock is currently owned by insiders.

CHMA has been the topic of a number of analyst reports. Cantor Fitzgerald set a $18.00 price objective on Chiasma and gave the stock a “buy” rating in a research note on Friday, June 28th. Brookline Capital Management reaffirmed a “buy” rating on shares of Chiasma in a report on Wednesday, July 24th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Chiasma in a report on Tuesday, July 23rd. ValuEngine lowered Chiasma from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research lowered Chiasma from a “buy” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $12.35.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: What is insider trading?

Want to see what other hedge funds are holding CHMA? Visit to get the latest 13F filings and insider trades for Chiasma Inc (NASDAQ:CHMA).

Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.